TY - JOUR
T1 - Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer
AU - Seski, Jan C.
AU - Edwards, Creighton L.
AU - Gershenson, David M.
AU - Copeland, Larry J.
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1981/7
Y1 - 1981/7
N2 - Twenty-six cases of metastatic adenocarcinoma of the endometrium treated with doxorubicin hydrochloride (Adriamycin) and cyclophosphamide at M. D. Anderson Hospital and Tumor Institute were retrospectively analyzed. Thirteen patients were treated initially for disseminated disease and 13 for a recurrence. Eight of 26 patients, or 31%, showed a partial response. There were no complete responses. The median duration of remission was 4 months, with a range of 2 to 12 months. Previous exposure to progestins did not significantly affect subsequent response to doxorubicin and cyclophosphamide. Toxicity from chemotherapy was moderate. Four patients (15%) developed serious myelosuppression, 2 developed cardiac arrhythmia, and 1 developed a doxorubicin extravasation. No deaths were attributable to chemotherapy. The combination of doxorubicin and cyclophosphamide has demonstrable, albeit limited, activity against metastatic endometrial cancer.
AB - Twenty-six cases of metastatic adenocarcinoma of the endometrium treated with doxorubicin hydrochloride (Adriamycin) and cyclophosphamide at M. D. Anderson Hospital and Tumor Institute were retrospectively analyzed. Thirteen patients were treated initially for disseminated disease and 13 for a recurrence. Eight of 26 patients, or 31%, showed a partial response. There were no complete responses. The median duration of remission was 4 months, with a range of 2 to 12 months. Previous exposure to progestins did not significantly affect subsequent response to doxorubicin and cyclophosphamide. Toxicity from chemotherapy was moderate. Four patients (15%) developed serious myelosuppression, 2 developed cardiac arrhythmia, and 1 developed a doxorubicin extravasation. No deaths were attributable to chemotherapy. The combination of doxorubicin and cyclophosphamide has demonstrable, albeit limited, activity against metastatic endometrial cancer.
UR - http://www.scopus.com/inward/record.url?scp=0019433670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019433670&partnerID=8YFLogxK
M3 - Article
C2 - 7195533
AN - SCOPUS:0019433670
SN - 0029-7844
VL - 58
SP - 88
EP - 91
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 1
ER -